The share price of US-based Nabi Biopharmaceuticals has fallen by 70 per cent after it announced that its nicotine addiction treatment, NicVax, failed to reach its endpoint in the first round of Phase III clinical trials. The drug helped subjects, of which there were 1000, quit smoking at a similar ...